Integra LifeSciences (NASDAQ:IART) Updates FY 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.400-2.500 for the period, compared to the consensus EPS estimate of 2.450. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q3 2026 guidance to 0.530-0.610 EPS.

Wall Street Analyst Weigh In

A number of brokerages have commented on IART. Citigroup reaffirmed a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Thursday, June 18th. Truist Financial lifted their target price on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Finally, BMO Capital Markets assumed coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $18.43.

Integra LifeSciences Trading Up 1.2%

Shares of Integra LifeSciences stock opened at $19.76 on Wednesday. The stock has a market cap of $1.54 billion, a PE ratio of -3.06, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22. The firm has a fifty day moving average price of $17.61 and a 200 day moving average price of $13.41. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $20.49. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IART. Rubric Capital Management LP boosted its position in Integra LifeSciences by 1.3% in the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after purchasing an additional 100,000 shares in the last quarter. Invesco Ltd. grew its stake in shares of Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after purchasing an additional 31,931 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Integra LifeSciences by 9.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares in the last quarter. State Street Corp lifted its stake in shares of Integra LifeSciences by 0.8% in the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock valued at $34,933,000 after purchasing an additional 21,717 shares during the period. Finally, Paradigm Capital Management Inc. NY lifted its stake in shares of Integra LifeSciences by 5.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock valued at $33,099,000 after purchasing an additional 135,198 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.